摘要
目的:检测乳腺癌患者血浆纤溶分子标志物含量、mRNA水平的变化以探索其与肿瘤浸润、播散的关系及临床意义。方法:采用逆转录、实时定量PCR技术检测30例乳腺癌组织中组织型纤溶酶原激活剂(tPA)、尿激酶型纤溶酶原激活剂(uPA)mRNA水平;用ELISA法同步检测患者血浆纤溶分子标志物含量,包括tPA、uPA、尿激酶型纤溶酶原激活剂受体(uPAR)、纤溶酶抗纤溶酶复合物(PAP)等。结果:乳腺癌患者血浆uPA、uPAR、PAP含量均较正常对照明显升高,其中,有周围淋巴结转移、远处脏器转移者uPA升高更为显著。肿瘤细胞uPAmRNA表达增高,在不同临床分期组中有显著差异,而tPAmRNA则减少。雌孕激素受体双阳性组tPAmRNA表达较其他组为高。结论:乳腺癌患者纤溶功能明显亢进,可能是其易播散、浸润的主要原因之一。逆转录实时定量PCR技术,使tPAmRNA、uPAmRNA有望成为临床上乳腺癌病情监测、预后判断及治疗选择的辅助指标。
Objective：To detect the mRNA expression breast cancer and to elucidate their relationship with tumor and plasma content of fibrinolysis molecular markers in patients with nvasion and metastasis and clinical significance. Methods： The mRNA expression of tissue type plasminogen activator （t-PA）, urokinase type plasminogen activator （u-PA） in 30 breast cancer tissues was determined by reverse transcriptase-real time polymerase chain reaction. The plasma content of fibrinolysis molecular markers such as t-PA,u-PA, urokinase-type plasminogen activator receptor （u-PAR）, and plasmin anti plasmin complex （PAP） were measured by ELISA. Results：The plasma levels of u-PA, u-PAR, and PAP were elevated in breast cancer patients compared with normal control. The plasma level of u PA was remarkably elevated in patients with lymph node involvement or distal metastasis. Expression of u-PA mRNA increased in breast cancer tissues compared with normal control. The difference was significant between different clinical stages. Expression of t-PA mRNA decreased in breast cancer tissues compared with normal control. It was significantly higher in estrogen receptors （ER） and progesterone receptors （PR）-double positive group. Conclusion： Hyperfibrinolysis was an important factor related with the potential of invasion and metastasis of breast cancer. With the help of reverse transcriptase-real time quantitative PCR, t-PA and u PA mRNA could be used as the assistant markers for supervision of breast cancer, evaluation of prognosis, and selection of therapeutic regimen.
出处
《肿瘤》
CAS
CSCD
北大核心
2006年第4期370-373,共4页
Tumor
关键词
乳腺肿瘤
纤溶酶原激活剂
基因表达
预后
Breast neoplasms
Plasminogen activators
Gene expression
Prognosis
